Table I.
Characteristics of AML1/ETO+ patients with or without EML.
| Characteristics | EML+ | EML− | P-value |
|---|---|---|---|
| No. of patients | 36 | 87 | |
| Male/female, n | 26/10 | 46/41 | 0.048 |
| Median age (range), years | 30.5 (2–69) | 25.0 (3–74) | 0.295 |
| Median WBC (range), ×109 cells/l | 21.7 (1.8–79.3) | 13.6 (1.1–85.8) | 0.059 |
| C-KIT mutation, n (%)a | |||
| Positive | 9 (39.1) | 14 (23.7) | 0.163 |
| Negative | 14 (60.9) | 45 (76.3) | |
| FLT3-ITD, n (%)a | |||
| Positive | 1 (4.3) | 2 (3.4) | 0.836 |
| Negative | 22 (95.7) | 57 (96.6) | |
| Expression of APP gene, n (%) | |||
| High | 11 (91.7) | 20 (41.7) | 0.019 |
| Low | 1 (8.3) | 28 (58.3) | |
| Induction therapy, n (%) | |||
| DA | 10 (30.3) | 20 (23.3) | |
| IA | 15 (45.5) | 46 (53.5) | 0.648 |
| Other | 8 (24.2) | 20 (23.3) | |
| Consolidation therapy, n (%) | |||
| Regimen 1 | 17 (58.6) | 31 (38.8) | |
| Regimen 2 | 8 (27.6) | 34 (42.5) | 0.179 |
| Regimen 3 | 4 (13.8) | 15 (18.8) | |
| IT, n (%) | |||
| ≤2 | 11 (31.0) | 37 (42.5) | 0.415 |
| >2 | 25 (69.0) | 50 (57.5) | |
| Outcomes of therapy, % | |||
| Rate of RFS | 34.5 | 68.8 | <0.001 |
| Rate of OS | 48.3 | 73.8 | 0.003 |
a
c-kit mutation and FLT3-ITD mutation data were not collected for all patients. WBC, white blood cell; FLT3-ITD, mutation in the FMS-like tyrosine kinase 3 gene; DA, cytarabine plus daunorubicin; IA, cytarabine plus idarubicin; IT, intrathecal injection; OS, overall survival; RFS, relapse-free survival; APP, amyloid precursor protein; EML, extramedullary leukemia.